| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PI-103 | GDSC1000 | pan-cancer | AAC | 0.082 | 0.01 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.01 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | 0.1 | 0.01 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.094 | 0.01 |
| mRNA | tandutinib | CTRPv2 | pan-cancer | AAC | -0.092 | 0.01 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.02 |
| mRNA | BRD-K99006945 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.02 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | 0.092 | 0.02 |
| mRNA | Repligen 136 | CTRPv2 | pan-cancer | AAC | -0.093 | 0.02 |